GO:0050748 negative regulation of lipoprotein metabolic process: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050748 describes any process that stops, prevents, or reduces the frequency, rate or extent of lipoprotein metabolism, a key control point in cholesterol and lipid homeostasis.
• Lipoprotein metabolism is regulated by hormone receptors, intracellular trafficking proteins such as Rab1b, and membrane lipids like PI(4,5)P2.
• Dysregulation of this process contributes to atherosclerosis, cardiovascular disease, and metabolic disorders, making it a target for therapeutic intervention.
• Key experimental models include knockout and knock-in cell lines, overexpression systems, and CRISPR library screening to identify causal genes.
• The term is distinct from positive regulation and is essential for understanding how cells maintain lipid balance and respond to hormonal signals.
• Research methods such as RNA-seq, proteomics, and imaging are used to dissect the molecular players and pathways involved.
Description
Lipoproteins are water-soluble complexes of lipids and proteins that transport cholesterol, triglycerides, and other lipids through the bloodstream. The metabolic processes involving lipoproteins are tightly controlled to maintain lipid homeostasis, and their negative regulation—captured by the Gene Ontology term GO:0050748—is critical for preventing excessive lipid accumulation and related diseases. This term encompasses any mechanism that reduces the frequency, rate, or extent of lipoprotein metabolism, including hormonal signals, intracellular trafficking, and membrane lipid interactions. Understanding negative regulation of lipoprotein metabolic process is essential for researchers studying cardiovascular disease, metabolic syndrome, and lipid disorders, as it provides a framework for identifying therapeutic targets and designing experiments to modulate lipoprotein levels.
negative regulation of lipoprotein metabolic process At A Glance
| GO ID | GO:0050748 |
|---|---|
| GO term | negative regulation of lipoprotein metabolic process |
| Ontology | biological_process |
| Synonym | down regulation of lipoprotein metabolic process; down-regulation of lipoprotein metabolic process; downregulation of lipoprotein metabolic process; inhibition of lipoprotein metabolic process; negative regulation of lipoprotein metabolism |
| Major function | Reduces the frequency, rate, or extent of lipoprotein metabolism, impacting lipid transport and homeostasis. |
| Regulatory inputs | Hormone receptors, Rab1b, PI(4,5)P2, and small-molecule inhibitors. |
| Disease relevance | Atherosclerosis, cardiovascular disease, metabolic disorders. |
| Experimental models | Knockout, knock-in, overexpression cell lines, CRISPR screening. |
What Is GO:0050748?
GO:0050748, negative regulation of lipoprotein metabolic process, refers to any biological process that stops, prevents, or reduces the frequency, rate, or extent of the chemical reactions and pathways involving lipoproteins. Lipoproteins are conjugated, water-soluble proteins in which the nonprotein group consists of a lipid or lipids. This regulation can occur at multiple levels, including receptor-mediated signaling, intracellular protein trafficking, and membrane lipid composition, ultimately controlling the availability and processing of lipoproteins.
Why Is negative regulation of lipoprotein metabolic process Important in Cell Biology?
Negative regulation of lipoprotein metabolic process is vital because it prevents excessive lipid accumulation and maintains cardiovascular health. Dysregulation of this process leads to elevated plasma cholesterol and triglycerides, which are major risk factors for atherosclerosis, heart attack, and stroke. Moreover, understanding how hormones, intracellular trafficking proteins, and membrane lipids negatively regulate lipoprotein metabolism can reveal new therapeutic strategies, such as PCSK9 inhibitors like evolocumab, which lower LDL cholesterol by modulating lipoprotein clearance.
• Controls plasma cholesterol and triglyceride levels, reducing cardiovascular risk.
• Mediates hormonal regulation of lipid metabolism via nuclear receptors.
• Involves intracellular trafficking proteins like Rab1b that affect lipoprotein secretion.
• Membrane lipid PI(4,5)P2 regulates cholesterol levels and lipoprotein metabolism.
• Small-molecule inhibitors of lipoprotein trafficking are potential antibiotics.
• Surface lipoprotein sorting in bacteria involves Lpt and Lol pathways, relevant to infection.
• Dysregulation contributes to atherosclerosis and metabolic syndrome.
• Therapeutic targeting can lower LDL cholesterol, as with evolocumab.
• Provides a framework for CRISPR screens to identify novel regulators.
• Essential for understanding lipid homeostasis in health and disease.
What Happens During negative regulation of lipoprotein metabolic process?
Hormonal and Receptor-Mediated Regulation
In simple terms: Hormones can bind to receptors and send signals that slow down lipoprotein metabolism.
Hormone receptors play a key role in regulating lipoprotein metabolism. For example, nuclear receptors can be activated by hormones to modulate gene expression, leading to reduced lipoprotein production or increased clearance. This negative regulation helps maintain lipid homeostasis in response to physiological cues.
Intracellular Trafficking and Secretion
In simple terms: Proteins inside cells control how lipoproteins are packaged and released.
Rab1b is a small GTPase that differentially regulates lipoprotein and hepatitis C virus secretion. Its activity can negatively regulate lipoprotein metabolic process by affecting the secretory pathway. This highlights the importance of intracellular trafficking in controlling lipoprotein levels.
Membrane Lipid Composition
In simple terms: Lipids in cell membranes can influence how cholesterol and lipoproteins are handled.
PI(4,5)P2, a membrane phospholipid, regulates plasma cholesterol levels. It can negatively regulate lipoprotein metabolic process by modulating the activity of enzymes and transporters involved in cholesterol homeostasis. This demonstrates the interplay between membrane lipids and lipoprotein metabolism.
Small-Molecule Inhibition
In simple terms: Certain chemicals can block lipoprotein trafficking, reducing lipoprotein metabolism.
Small-molecule inhibitors of gram-negative lipoprotein trafficking have been discovered through phenotypic screening. These compounds inhibit the transport of lipoproteins, thereby negatively regulating lipoprotein metabolic process and offering potential antibacterial strategies.
Bacterial Lipoprotein Sorting
In simple terms: In bacteria, lipoproteins are sorted to different locations, and this process can be regulated.
Surface lipoprotein sorting in gram-negative bacteria involves crosstalk between the Lpt and Lol pathways. This sorting mechanism can negatively regulate lipoprotein metabolic process by ensuring proper localization and preventing mislocalization.
Key Genes Involved in GO:0050748 negative regulation of lipoprotein metabolic process
The following genes and proteins are key players in the negative regulation of lipoprotein metabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H3 | Nuclear receptor involved in lipid metabolism | Hormonal regulation of lipoprotein metabolism |
| NR1H2 | Nuclear receptor that modulates cholesterol homeostasis | Target for dyslipidemia |
| RAB1B | GTPase regulating secretory pathway | Differential regulation of lipoprotein secretion |
| PCSK9 | Proprotein convertase that degrades LDL receptor | Target of evolocumab for lowering LDL |
| LDLR | Receptor mediating LDL uptake | Key regulator of plasma cholesterol |
| APOB | Apolipoprotein component of LDL | Structural and functional role in lipoproteins |
| APOE | Apolipoprotein involved in lipid transport | Risk factor for Alzheimer's and cardiovascular disease |
| LPL | Lipoprotein lipase hydrolyzes triglycerides | Regulates lipoprotein metabolism |
| CETP | Cholesteryl ester transfer protein | Modulates HDL and LDL levels |
| ABCG1 | Cholesterol transporter | Regulates cellular cholesterol efflux |
| ABCG5 | Sterol transporter | Controls cholesterol absorption |
| LIPC | Hepatic lipase | Influences lipoprotein remodeling |
| LPA | Lipoprotein(a) component | Cardiovascular risk factor |
| LPL | Lipoprotein lipase | Hydrolyzes triglycerides in lipoproteins |
| LIPG | Endothelial lipase | Regulates HDL metabolism |
| SOAT1 | Sterol O-acyltransferase | Cholesterol esterification |
| NPC1L1 | Cholesterol absorption transporter | Target of ezetimibe |
How Is negative regulation of lipoprotein metabolic process Regulated?
Negative regulation of lipoprotein metabolic process is controlled at multiple levels. Hormone receptors, such as nuclear receptors, can be activated by ligands to modulate gene expression and reduce lipoprotein production. Intracellular trafficking proteins like Rab1b affect the secretion of lipoproteins, thereby regulating their availability. Membrane lipids, particularly PI(4,5)P2, influence cholesterol levels and lipoprotein metabolism. Additionally, small-molecule inhibitors can block lipoprotein trafficking, providing a means to pharmacologically regulate the process. These regulatory mechanisms ensure tight control of lipid homeostasis.
negative regulation of lipoprotein metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCSK9 | Hypercholesterolemia | Knockout cell line to study LDL uptake |
| LDLR | Familial hypercholesterolemia | Knock-in of mutant LDLR |
| APOE | Alzheimer's disease, cardiovascular disease | Knock-in mouse model |
| RAB1B | Hepatitis C virus secretion | Knockout cell line to assess lipoprotein secretion |
| ABCG1 | Tangier disease | Overexpression cell model |
Atherosclerosis and Cardiovascular Disease
Dysregulation of lipoprotein metabolism, particularly impaired negative regulation, leads to elevated LDL cholesterol and triglycerides, which are major risk factors for atherosclerosis. The accumulation of lipoproteins in arterial walls promotes plaque formation and cardiovascular events. Therapeutic agents like evolocumab, which inhibit PCSK9 and enhance LDL clearance, demonstrate the clinical importance of modulating this process.
Metabolic Syndrome and Diabetes
Insulin resistance and metabolic syndrome are associated with altered lipoprotein metabolism. Negative regulation of lipoprotein metabolic process is impaired in these conditions, contributing to dyslipidemia and increased cardiovascular risk. Understanding the molecular players, such as nuclear receptors and Rab1b, may offer new therapeutic avenues.
Bacterial Infections
In gram-negative bacteria, lipoprotein trafficking is essential for outer membrane integrity. Small-molecule inhibitors of lipoprotein trafficking have been identified, and these compounds negatively regulate lipoprotein metabolic process, offering potential antibacterial strategies. Surface lipoprotein sorting pathways are also targets for novel antibiotics.
From negative regulation of lipoprotein metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate lipoprotein metabolism? | Knockout cell line (e.g., HepG2) |
| What is the effect of a point mutation in gene Y? | Point-mutation knock-in cell line |
| How does overexpression of gene Z affect lipoprotein levels? | Overexpression cell model |
| Can we identify novel regulators via CRISPR screen? | CRISPR library screening in hepatocytes |
| What is the role of Rab1b in lipoprotein secretion? | Knockout and rescue experiments |
| How does PI(4,5)P2 regulate cholesterol? | Knock-in of PI(4,5)P2 binding mutants |
How to Study the negative regulation of lipoprotein metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify pathways altered by negative regulators |
| Proteomics | Protein abundance and modifications | Quantify lipoprotein-associated proteins |
| Lipidomics | Lipid species and concentrations | Measure cholesterol and triglyceride levels |
| Imaging | Subcellular localization and trafficking | Track lipoprotein secretion |
| CRISPR screen | Gene function on a genome-wide scale | Discover novel negative regulators |
| Western blot | Protein expression and phosphorylation | Validate knockout or overexpression |
| qPCR | mRNA levels | Confirm gene expression changes |
| Luciferase reporter | Transcriptional activity | Assess promoter regulation |
RNA-seq and Transcriptomics
RNA sequencing can measure changes in gene expression related to lipoprotein metabolism after genetic perturbations. This method helps identify pathways and networks affected by negative regulators.
Proteomics and Lipidomics
Mass spectrometry-based proteomics and lipidomics quantify protein and lipid species, revealing how negative regulation alters lipoprotein composition and abundance.
Imaging and Trafficking Assays
Fluorescence microscopy and live-cell imaging track the movement of lipoproteins and associated proteins, such as Rab1b, to visualize negative regulation of secretion.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate lipoprotein metabolic process, providing unbiased discovery of novel regulators.
How CRISPR Can Be Used to Study GO:0050748 negative regulation of lipoprotein metabolic process
Knockout
CRISPR knockout cell lines are used to delete genes suspected to negatively regulate lipoprotein metabolism. For example, knocking out RAB1B can reveal its role in lipoprotein secretion. Knockout of PCSK9 in hepatocytes increases LDL receptor levels, demonstrating negative regulation.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to disrupt specific functional domains. For instance, mutating PI(4,5)P2 binding sites in regulatory proteins can elucidate their role in cholesterol homeostasis.
Knock-in
Knock-in of tagged or reporter genes allows visualization and tracking of proteins involved in lipoprotein metabolism. This approach can be used to study the localization and dynamics of Rab1b or nuclear receptors.
Overexpression
Overexpression of candidate negative regulators can suppress lipoprotein metabolism, providing gain-of-function evidence. For example, overexpressing ABCG1 enhances cholesterol efflux and reduces lipoprotein levels.
How EDITGENE Supports negative regulation of lipoprotein metabolic process Research
Researchers studying negative regulation of lipoprotein metabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid homeostasis. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipoprotein metabolic process research.
Frequently Asked Questions About negative regulation of lipoprotein metabolic process
What is GO:0050748?
GO:0050748 is the Gene Ontology term for negative regulation of lipoprotein metabolic process, describing any process that reduces the frequency, rate, or extent of lipoprotein metabolism.
What genes are involved in negative regulation of lipoprotein metabolic process?
Key genes include NR1H3, NR1H2, RAB1B, PCSK9, LDLR, APOB, APOE, LPL, CETP, ABCG1, and others.
How is lipoprotein metabolism negatively regulated?
It is regulated by hormone receptors, intracellular trafficking proteins like Rab1b, membrane lipids such as PI(4,5)P2, and small-molecule inhibitors.
What diseases are associated with dysregulation of this process?
Atherosclerosis, cardiovascular disease, metabolic syndrome, and bacterial infections are linked to dysregulation.
What experimental models are used to study GO:0050748?
Knockout, knock-in, overexpression cell lines, and CRISPR screens are commonly used.
How can CRISPR be used to study negative regulation of lipoprotein metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes involved.
What is the role of Rab1b in lipoprotein metabolism?
Rab1b differentially regulates lipoprotein and hepatitis C virus secretion, acting as a negative regulator.
How does PI(4,5)P2 regulate cholesterol levels?
PI(4,5)P2 modulates plasma cholesterol levels by affecting enzymes and transporters in lipoprotein metabolism.
What are small-molecule inhibitors of lipoprotein trafficking?
These are compounds discovered through phenotypic screening that block lipoprotein transport, offering antibacterial potential.
Why is negative regulation of lipoprotein metabolism important?
It maintains lipid homeostasis and prevents cardiovascular disease; its dysregulation leads to hypercholesterolemia and atherosclerosis.
Conclusion
Negative regulation of lipoprotein metabolic process (GO:0050748) is a critical biological process that controls lipid homeostasis and prevents disease. Key regulators include hormone receptors, Rab1b, PI(4,5)P2, and small-molecule inhibitors, with implications for cardiovascular disease and bacterial infections. Advances in CRISPR technology and omics methods are accelerating the discovery of novel players and therapeutic targets. EDITGENE provides essential tools and services to support this research.
References
- 1. Baxter JD et al.. 1979. Hormone receptors.. N Engl J Med 301(21):1149-61 PMID: 226885
- 2. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 3. Takacs CN et al.. 2017. Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b.. Cell Rep 21(2):431-441 PMID: 29020629
- 5. McLeod SM et al.. 2015. Small-molecule inhibitors of gram-negative lipoprotein trafficking discovered by phenotypic screening.. J Bacteriol 197(6):1075-82 PMID: 25583975
- 6. Luo Q et al.. 2025. Surface lipoprotein sorting by crosstalk between Lpt and Lol pathways in gram-negative bacteria.. Nat Commun 16(1):4357 PMID: 40348743
- 7. Qin Y et al.. 2023. Mechanism of the Regulation of Plasma Cholesterol Levels by PI(4,5)P(2).. Adv Exp Med Biol 1422:89-119 PMID: 36988878
- 8. Markham A. 2015. Evolocumab: First Global Approval.. Drugs 75(13):1567-73 PMID: 26323342
